ATOS · NASDAQ · Biotechnology

Atossa Therapeutics (ATOS)

Develops oral (Z)-endoxifen for breast cancer and selected rare diseases.

$2.22
vs last close−0.04 (−1.77%)
  1. New Strong Sell Stocks for Oct. 22

    Zacks Investment Research